Fosaprepitant Dimeglumine

福沙吡坦二甲葡胺

Report date: 2024/04/26 17:20:10
NME

Base Information

Drug NameFosaprepitant Dimeglumine
Drug Alias Name福沙匹坦fosaprepitantum磷阿瑞匹坦fosaprepitantFosaprepitant +[15] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNeurokinin 1 receptor antagonists
TargetsNeurokinin 1 receptor
Therapy Area/IndicationsChemotherapy-induced nausea and vomitingSolid tumoursVomiting +[8] 
Global Approved IndicationsChemotherapy-induced nausea and vomitingVomitingNausea
Approved Indications in ChinaVomitingNausea
Original Approved Country/TerritoryAustralia
Original Approved Date2007/08/14
Country/TerritoryUnited StatesAustraliaGermany +[6] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesMerck Sharp & Dohme BvMerck & Co IncJiangsu Hansoh Pharmaceutical Group Co Ltd +[6] 
Inactive CompaniesOhsu Knight Cancer InstituteHeidelberg UniversitySaint Louis University +[9] 
Active IndicationsChemotherapy-induced nausea and vomitingVomitingNausea +[4] 
Inactive IndicationsSolid tumoursPostoperative Nausea and VomitingCarcinoma, Non-Small-Cell Lung +[4] 

Other Information

ATC CodeA04AD12
Related LinksWikipediaDrugBankKEGG